Feb 27, 2026 08:59AM ALX Oncology Holdings Inc. (ALXO) Misses Q4 EPS by 7c

Jan 30, 2026 08:31AM ALX Oncology prices $150 million stock and warrant offering

Jan 30, 2026 08:15AM ALX Oncology finds CD47 expression predicts breast cancer treatment response

Nov 20, 2025 03:59AM Jefferies Reiterates Buy Rating on ALX Oncology (ALXO)

Nov 13, 2025 05:03AM Jefferies Starts ALX Oncology (ALXO) at Buy

Nov 7, 2025 04:37PM ALX Oncology Holdings Inc. (ALXO) Misses Q3 EPS by 4c

Aug 12, 2025 04:49PM ALX Oncology Holdings Inc. (ALXO) Misses Q2 EPS by 6c

May 27, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on ALX Oncology (ALXO)

May 8, 2025 05:12PM ALX Oncology Holdings Inc. (ALXO) Misses Q1 EPS by 6c

Apr 25, 2025 01:10PM ALX Oncology (ALXO) Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025 09:01AM ALX Oncology (ALXO) Says ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Apr 7, 2025 08:01AM ALX Oncology (ALXO) Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

Mar 7, 2025 09:01AM ALX Oncology (ALXO) PT Lowered to $1.50 at Stifel

Mar 6, 2025 05:19PM ALX Oncology Holdings Inc. (ALXO) Tops Q4 EPS by 12c

Mar 6, 2025 02:14AM Jefferies Upgrades ALX Oncology (ALXO) to Buy

Jan 27, 2025 10:36AM ALX Oncology (ALXO) PT Lowered to $2.20 at UBS

Jan 24, 2025 10:10AM Stifel Reiterates Hold Rating on ALX Oncology (ALXO)

Jan 24, 2025 07:28AM Cantor Fitzgerald Reiterates Overweight Rating on ALX Oncology (ALXO)

Jan 24, 2025 06:39AM ALX Oncology (ALXO) PT Lowered to $5 at H.C. Wainwright

Jan 23, 2025 08:00AM ALX Oncology (ALXO) Presents Positive Updated Data from ASPEN-06 Phase 2 Trial

Dec 19, 2024 03:12AM Jefferies Downgrades ALX Oncology (ALXO) to Hold

Dec 18, 2024 09:13AM Stifel Reiterates Hold Rating on ALX Oncology (ALXO)

Dec 10, 2024 09:01AM ALX Oncology (ALXO) Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

Nov 14, 2024 08:01AM ALX Oncology (ALXO) Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 8, 2024 06:27AM ALX Oncology Holdings Inc. (ALXO) Tops Q3 EPS by 20c

Aug 21, 2024 05:22AM Increasing unusual option volume: HP LUNR MFC GDS VIPS NMM K HA COTY ALXO

Aug 12, 2024 05:11AM Increasing unusual option volume: NNOX ALXO AUPH PUBM APPS DOCS ALIT LUMN

Aug 9, 2024 07:11AM ALX Oncology Holdings Inc. (ALXO) Misses Q2 EPS by 2c

Aug 6, 2024 04:01PM ALX Oncology (ALXO) Appoints Alan Sandler to its Board

Jul 31, 2024 04:03PM ALX Oncology (ALXO) Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024 06:51AM ALX Oncology (ALXO) to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 10, 2024 08:47AM UBS Reiterates Buy Rating on ALX Oncology (ALXO)

Jun 10, 2024 06:53AM Piper Sandler Reiterates Overweight Rating on ALX Oncology (ALXO)